2024
Randomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147)
Sheth S, Oh J, Bellone S, Siegel E, Greenman M, Mutlu L, McNamara B, Pathy S, Clark M, Azodi M, Altwerger G, Andikyan V, Huang G, Ratner E, Kim D, Iwasaki A, Levi A, Buza N, Hui P, Flaherty S, Schwartz P, Santin A. Randomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147). Clinical Cancer Research 2024, 30: of1-of10. PMID: 38592381, DOI: 10.1158/1078-0432.ccr-23-3639.Peer-Reviewed Original ResearchConceptsRandomized phase II trialCD4/CD8 T cellsT cellsHPV clearanceArm BNo significant differenceClinical surveillanceRate of HPV clearanceSecondary outcomesPre-neoplastic cervical lesionsCervical intraepithelial neoplasiaT cell infiltrationT cell responsesSignificant differenceCIN3 patientsIntraepithelial neoplasiaArm ACervical lesionsImiquimod groupSurveillance armVaginal suppositoriesProspective trialsArm CHPV vaccinationImiquimod
2006
Survival and toxicity differences between 5‐day and weekly cisplatin in patients with locally advanced cervical cancer
Einstein MH, Novetsky AP, Garg M, Hailpern SM, Huang GS, Glueck A, Fields AL, Kalnicki S, Goldberg GL. Survival and toxicity differences between 5‐day and weekly cisplatin in patients with locally advanced cervical cancer. Cancer 2006, 109: 48-53. PMID: 17123270, DOI: 10.1002/cncr.22369.Peer-Reviewed Original ResearchConceptsProgression-free survivalAdvanced cervical cancerCervical cancerWeekly groupWeekly CDDPAdvanced stage cervical cancerAdvanced-stage patientsCompletion of treatmentTimes higher riskExternal beam radiotherapyAcute toxicitySignificant demographic differencesOutpatient regimenWeekly cisplatinWeekly regimenConsecutive patientsTreatment failureSingle institutionDay concomitantBeam radiotherapyHigh riskRate brachytherapy treatmentPatientsRegimenRadiotherapy
2005
Total laparoscopic hysterectomy versus total abdominal hysterectomy: cohort review of patients with uterine neoplasia.
O'Hanlan KA, Huang GS, Garnier AC, Dibble SL, Reuland ML, Lopez L, Pinto RL. Total laparoscopic hysterectomy versus total abdominal hysterectomy: cohort review of patients with uterine neoplasia. JSLS Journal Of The Society Of Laparoscopic & Robotic Surgeons 2005, 9: 277-86. PMID: 16121872, PMCID: PMC3015616.Peer-Reviewed Original ResearchConceptsTotal laparoscopic hysterectomyUterine neoplasiaTAH groupBlood lossLaparoscopic hysterectomyTAH patientsTotal abdominal hysterectomy patientsSimilar body mass indexAbdominal hysterectomy patientsBulky metastatic diseaseTotal abdominal hysterectomyAverage blood lossLess blood lossBody mass indexClinical selection criteriaAbdominal hysterectomyHospital stayNode dissectionChart abstractionCohort reviewMetastatic diseaseSelect patientsEndometrial pathologyHysterectomy patientsLaparoscopic approach
2004
Total laparoscopic hysterectomy for oncological indications with outcomes stratified by age
O'Hanlan KA, Huang GS, Lopez L, Garnier AC. Total laparoscopic hysterectomy for oncological indications with outcomes stratified by age. Gynecologic Oncology 2004, 95: 196-203. PMID: 15385132, DOI: 10.1016/j.ygyno.2004.07.023.Peer-Reviewed Original ResearchConceptsTotal laparoscopic hysterectomyBody mass indexOvarian carcinomaAdhesive bowel obstructionEarly ovarian carcinomaFamilial ovarian carcinomaMean blood lossOverall complication rateComplex pelvic massChi-square testUrologic complicationsBowel obstructionHospital stayComplication rateBlood lossCervical dysplasiaEndometrial neoplasiaLaparoscopic hysterectomyMass indexVaginal carcinomaPelvic massPreoperative diagnosisSurgical durationSurgical outcomesOncological indications
2003
Total laparoscopic hysterectomy: body mass index and outcomes.
O'Hanlan KA, Lopez L, Dibble SL, Garnier AC, Huang GS, Leuchtenberger M. Total laparoscopic hysterectomy: body mass index and outcomes. Obstetrics And Gynecology 2003, 102: 1384-92. PMID: 14662231, DOI: 10.1016/j.obstetgynecol.2003.08.018.Peer-Reviewed Original ResearchMeSH KeywordsBody Mass IndexFemaleHumansHysterectomyLaparoscopyMiddle AgedPostoperative ComplicationsRetrospective StudiesTreatment OutcomeConceptsTotal laparoscopic hysterectomyBody mass indexLaparoscopic hysterectomyBMI groupsHospital stayBlood lossComplication rateMass indexOccult ovarian carcinomaTotal complication rateShorter hospital stayMinor complication rateMinimal blood lossOperating timeOverweight-25Urologic injuryAbdominal surgeryBMI categoriesInvasive hysterectomyLaparoscopic approachPatient seriesRetrospective reviewMean ageOvarian carcinomaMinimal operating time